|Articles|October 12, 2020
Size Exclusion Chromatography Method Development of NIST mAb Using an Agilent AdvanceBio SEC 200 Å 1.9 μm Column
Author(s)Agilent Technologies
Learn how to perform method optimization using a bio-inert quaternary LC instrument to screen multiple mobile phase compositions for aggregate analysis of NIST mAb.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5